Edition:
India

BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

30.60USD
12:35am IST
Change (% chg)

$2.39 (+8.47%)
Prev Close
$28.21
Open
$29.30
Day's High
$30.60
Day's Low
$29.09
Volume
5,965
Avg. Vol
1,131
52-wk High
$48.42
52-wk Low
$16.65

Chart for

About

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase... (more)

Overall

Beta: --
Market Cap(Mil.): $892.10
Shares Outstanding(Mil.): 22.84
Dividend: --
Yield (%): --

Financials

BRIEF-BeyondSpring Appoints Patrick Fabbio To Board As An Independent Member

* BEYONDSPRING APPOINTS LIFE SCIENCES VETERAN PATRICK FABBIO TO BOARD OF DIRECTORS AS AN INDEPENDENT MEMBER Source text for Eikon: Further company coverage:

03 Jan 2018

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)

14 Dec 2017

BRIEF-Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China

* BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY

30 Nov 2017

BRIEF-BeyondSpring qtrly loss per share $‍0.68

* BeyondSpring reports third quarter 2017 operational and financial results

09 Nov 2017

BRIEF-BeyondSpring announces first patient enrolled in China

* BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia

26 Oct 2017

Earnings vs. Estimates